Skip to main content

Advertisement

Log in

Diabetes and HIV: Current Understanding and Future Perspectives

  • Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetes mellitus is a chronic disease with a higher risk of associated infections. HIV infection severely affects diabetic patients and acts as a significant health concern. Highly active antiretroviral therapy (HAART) has changed HIV from an acute infection to a chronic infection with associated significant metabolic abnormalities such as insulin resistance, impaired glucose tolerance, metabolic syndrome, diabetes, dyslipidemia, obesity, and lipodystrophy. These metabolic disturbances add complexity to the standards of care in HIV infection and further increase the risk for cardiovascular disease and renal complications. The co-association of diabetes and HIV needs to be managed appropriately to prevent mortality and morbidity and improve patient outcome. The current understanding of diabetes and other metabolic abnormalities along with management strategies in HIV infected patients are summarized in this article. The review also focuses on recent challenges in the diagnosis and management of co-existent diabetes and HIV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •Global Report. UNAIDS Report on the Global AIDS Epidemic. 2010. Available at: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. The report gives the latest statistics for HIV worldwide.

  2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.

    Article  PubMed  CAS  Google Scholar 

  3. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–34.

    Article  PubMed  Google Scholar 

  4. ••Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, et al. Prevalence of diabetes mellitus, hyperinsulinaemia, and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22:43–5. A longer exposure to antiretroviral therapy and a diagnosis of lipodystrophy syndrome were significantly associated with both metabolic disturbances.

    Article  PubMed  CAS  Google Scholar 

  5. ••Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012;27(8):657–65. A recent study about prevalence of type 2 diabetes mellitus in HIV-infected subjects in healthy subjects.

  6. Hadigan C. Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep. 2006;8:69–75.

    Article  PubMed  Google Scholar 

  7. Florescu D, Kotler DP. Insulin resistance, glucose intolerance, and diabetes mellitus in HIV-infected patients. Antivir Ther. 2007;12:149–62.

    PubMed  CAS  Google Scholar 

  8. •Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9:206–17. A recent review about current evidence base and clinical guidelines for diabetes and lipid management and cardiometabolic prevention in HIV-infected HAART recipients.

    Article  PubMed  Google Scholar 

  9. Salehian B, Bilas J, Bazargan M, Abbasian M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc. 2005;97:1088–92.

    PubMed  Google Scholar 

  10. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res. 2006;4:79–85.

    Article  PubMed  CAS  Google Scholar 

  11. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423–30.

    Article  PubMed  CAS  Google Scholar 

  12. •Das S. Insulin resistance and diabetes in HIV infection. Recent Pat Antiinfect Drug Discov. 2011;6:260–8. The present review article has the information of patients regarding the insulin resistance in HIV infection.

    Article  PubMed  CAS  Google Scholar 

  13. •Krishnan S, Shouten JT, Atkinson B, Brown T, Wohl T, McComsey GA, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61(3):381–9. A recent study about the development of metabolic syndrome in HIV-infected individuals on ART, with virologic suppression and maintenance of high CD4+ T-cell counts as potentially modifiable factors that can reduce the risk of metabolic syndrome.

  14. Abdel-Khalek I, Moallem HJ, Fikrig S, Castells S. New onset diabetes mellitus in an HIV-positive adolescent. AIDS Patient Care STDS. 1998;12:167–9.

    Article  PubMed  CAS  Google Scholar 

  15. •Kalra S KB, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr. 2011;3(1):2. A review article on pathology of diabetes in HIV along with diagnosis and management.

  16. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.

    Article  PubMed  CAS  Google Scholar 

  17. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals vs individuals in the national health and nutritional examination survey cohort. J Acquir Immune Defic Syndr. 2007;45:66–71.

    Article  PubMed  Google Scholar 

  18. Kourtis AP, Bansil P, Kahn HS, Posner SF, Jamieson DJ. Diabetes trends in hospitalized HIV-infected persons in the United States, 1994-2004. Curr HIV Res. 2009;7:481–6.

    Article  PubMed  CAS  Google Scholar 

  19. Brambilla AM, Novati R, Calori G, Meneghini E, Vacchini D, Luzi L, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993–5.

    Article  PubMed  Google Scholar 

  20. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244–9.

    Article  PubMed  Google Scholar 

  21. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40:115–9.

    Article  PubMed  Google Scholar 

  22. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Clin Infect Dis. 2007;45:111–9.

    Article  PubMed  Google Scholar 

  23. Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's interagency HIV study. J Acquir Immune Defic Syndr. 2010;54:152–9.

    PubMed  Google Scholar 

  24. Monroe A. HIV/AIDS and diabetes: minimizing risk, optimizing care. BETA. 2009;21:38–44.

    PubMed  Google Scholar 

  25. Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–14.

    Article  PubMed  CAS  Google Scholar 

  26. Gonzalez-Tome MI, Ramos Amador JT, Guillen S, Solis I, Fernandez-Ibieta M, Munoz E, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med. 2008;9:868–74.

    Article  PubMed  CAS  Google Scholar 

  27. Gianotti N, Visco F, Galli L, Barda B, Piatti P, Salpietro S, et al. Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Med. 2011;12:109–17.

    Article  PubMed  CAS  Google Scholar 

  28. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.

    Article  PubMed  Google Scholar 

  29. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's interagency HIV study. AIDS. 2007;21:1739–45.

    Article  PubMed  CAS  Google Scholar 

  30. Srivanich N, Ngarmukos C, Sungkanuparph S. Prevalence of, and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand. J Int Assoc Physicians AIDS Care. 2010;9:358–61.

    Article  Google Scholar 

  31. Revuelta MP. Cumulative insults to mitochondrial function may promote the emergence of 'syndrome X' and diabetes mellitus in HIV/HCV co-infected patients. Mitochondrion. 2004;4:175–84.

    Article  PubMed  CAS  Google Scholar 

  32. Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, et al. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 2007;8:491–7.

    Article  PubMed  CAS  Google Scholar 

  33. Lo YC, Chang SY, Sheng WH, Hung CC, Chang SC. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature. Eur J Gastroenterol Hepatol. 2009;21:478–81.

    Article  PubMed  Google Scholar 

  34. Hamill M, Brook G. An association between HIV/HCV co-infection and diabetes mellitus–is there a need for routine blood glucose monitoring? J Clin Virol. 2005;33:176–8.

    Article  PubMed  CAS  Google Scholar 

  35. Rotger M, Gsponer T, Martinez R, Taffe P, Elzi L, Vernazza P, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis. 2010;51:1090–8.

    Article  PubMed  CAS  Google Scholar 

  36. Holly JM, Amiel SA, Sandhu RR, Rees LH, Wass JA. The role of growth hormone in diabetes mellitus. J Endocrinol. 1988;118:353–64.

    Article  PubMed  CAS  Google Scholar 

  37. Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol. 2002;56:493–501.

    Article  CAS  Google Scholar 

  38. Schauster AC, Geletko SM, Mikolich DJ. Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome. Pharmacotherapy. 2000;20:1129–34.

    Article  PubMed  CAS  Google Scholar 

  39. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr. 1999;21:209–16.

    Article  PubMed  CAS  Google Scholar 

  40. Trabattoni D, Schenal M, Cesari M, Castelletti E, Pacei M, Goldberg B, et al. Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. Med Microbiol Immunol. 2006;195:125–32.

    Article  PubMed  CAS  Google Scholar 

  41. Takarabe D, Rokukawa Y, Takahashi Y, Goto A, Takaichi M, Okamoto M, et al. Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy. J Clin Endocrinol Metab. 2010;95:4056–60.

    Article  PubMed  CAS  Google Scholar 

  42. Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, et al. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010;86:88–92.

    Article  PubMed  CAS  Google Scholar 

  43. ••Kalra SUA, Raza SA, Bantwal G, Baruah MP, Latt TS, Shrestha D, et al. South Asian consensus guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocr Metab. 2011;15:242–50. The recent South Asian Guidelines about diagnosis and management of diabetes in HIV patients.

    Article  Google Scholar 

  44. Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One. 2011;6:e25237.

    Article  PubMed  CAS  Google Scholar 

  45. Deloumeaux J, Maachi M, Sow-Goerger MT, Lamaury I, Velayoudom FL, Cheret A, et al. Adiponectin and leptin in afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes. Diabetes Metab. 2011;37:98–104.

    Article  PubMed  CAS  Google Scholar 

  46. Idiculla J, Ravindra'n GD, D'Souza J, Singh G, Furruqh S. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in south India. Int J Gen Med. 2011;4:73–8.

    Article  PubMed  CAS  Google Scholar 

  47. Garg H, Joshi A, Mukherjee D. Cardiovascular complications of HIV infection and treatment. Cardiovasc Hematol Agents Med Chem. 2012 Aug 30 Accessed 15 Sept 2012

  48. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation. 2009;119:805–11.

    Article  PubMed  Google Scholar 

  49. Calza L. Renal toxicity associated with antiretroviral therapy. HIV Clin Trials. 2012;13:189–211.

    Article  PubMed  CAS  Google Scholar 

  50. Cohen DB, Allain TJ, Glover S, Chimbayo D, Dzamalala H, Hofland HW, et al. A survey of the management, control, and complications of diabetes mellitus in patients attending a diabetes clinic in Blantyre, Malawi, an area of high HIV prevalence. AmJTrop Med Hyg. 2010;83:575–81.

    Article  Google Scholar 

  51. Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the veterans aging cohort study. J Acquir Immune Defic Syndr. 2012;60:393–9.

    Article  PubMed  Google Scholar 

  52. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. Racial differences in end-stage renal disease rates in HIV infection vs diabetes. J Am Soc Nephrol. 2007;18:2968–74.

    Article  PubMed  Google Scholar 

  53. Kim PS, Woods C, Dutcher L, Georgoff P, Rosenberg A, Mican JA, et al. Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One. 2011;6:e24610.

    Article  PubMed  CAS  Google Scholar 

  54. Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, et al. A1C underestimates glycemia in HIV infection. Diabetes Care. 2009;32:1591–3.

    Article  PubMed  CAS  Google Scholar 

  55. Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS. 2012;26:197–201.

    PubMed  Google Scholar 

  56. Tien PC, Schneider MF, Cox C, Karim R, Cohen M, Sharma A, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61(3):334–40.

    Google Scholar 

  57. Beatty GKM, Abbasi F, Chu J, Reaven GM, Rosen A, et al. Quantification of insulin-mediated glucose-disposal in HIV-infected individual: comparision of patients treated and untreated with protease inhibitors. J Acquir Immune Defic Syndr. 2003;33:34–40.

    Article  PubMed  CAS  Google Scholar 

  58. Fairchild AL, Alkon A. Back to the future? diabetes, HIV, and the boundaries of public health. J Health Polit Policy Law. 2007;32:561–93.

    Article  PubMed  Google Scholar 

  59. • American Diabetes Association (ADA) Clinical Practice Recommendations. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35:S11–63. Recent ADA guidelines about medical care in diabetes with focus on patient centric approach.

    Article  Google Scholar 

  60. Polo R, Jose Galindo M, Martinez E, Alvarez J, Arevalo JM, Asensi V. et al [recommendations of the study group for metabolic alterations/secretariat for the national AIDS plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection]. Enferm Infecc Microbiol Clin. 2006;24:96–117.

    Article  PubMed  Google Scholar 

  61. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472–7.

    Article  PubMed  CAS  Google Scholar 

  62. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2002;87:4611–5.

    Article  PubMed  CAS  Google Scholar 

  63. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.

    Article  PubMed  CAS  Google Scholar 

  64. Aberg JAKJ, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651–81.

    Article  PubMed  Google Scholar 

  65. Kalra S, Unnikrishnan AG, Raza SA, Bantwal G, Baruah MP, Latt TS, et al. South Asian consensus guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocrinol Metab. 2011;15:242–50.

    Article  PubMed  Google Scholar 

  66. Kalra SKB, Nanda G. OPD management of ketosis in pregnancy: aspart vs regular insulin. Diabet Med. 2006;23:504.

    Google Scholar 

  67. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

    Google Scholar 

  68. Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation. 2009;119:770–2.

    Article  PubMed  Google Scholar 

  69. Dube MPSD, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clin Infect Dis. 2000;31:1216–24.

    Article  PubMed  CAS  Google Scholar 

  70. Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, et al. A randomized, open-label comparison of 3 highly active antiretroviral therapy regimens including 2 nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171–80.

    Article  PubMed  CAS  Google Scholar 

  71. Janssens B, Van Damme W, Raleigh B, Gupta J, Khem S, Soy Ty K, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia. Bull World Health Organ. 2007;85:880–5.

    PubMed  CAS  Google Scholar 

  72. Tzoupis H, Leonis G, Megariotis G, Supuran CT, Mavromoustakos T, Papadopoulos MG. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. J Med Chem. 2012;55:5784–96.

    Article  PubMed  CAS  Google Scholar 

  73. Questions and answers on the review aliskiren-containing medicines: European Medicines Agency. 2012.

  74. Pandey K, Sinha PK, Rabidas V, Kumar N, Bimal S, Verma N, et al. HIV, visceral leishmaniasis, and Parkinsonism combined with diabetes mellitus and hyperuricaemia: a case report. Cases J. 2008;1:183.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

Sanjay Kalra declares that he has no conflict of interest. Navneet Agrawal declares that he has no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sanjay Kalra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalra, S., Agrawal, N. Diabetes and HIV: Current Understanding and Future Perspectives. Curr Diab Rep 13, 419–427 (2013). https://doi.org/10.1007/s11892-013-0369-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-013-0369-9

Keywords

Navigation